Global Castration Resistant Prostate Cancer Treatment Market is Segmented By Treatment (Chemotherapy, Hormonal therapy, Targeted therapy, Surgery, Others), By End-users (Hospitals, Specialty Clinics, Diagnostic laboratory, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Castration Resistant Prostate Cancer Treatment Market Overview
The Global Castration Resistant Prostate Cancer Treatment Market is expected to grow at a CAGR of 9% during the forecasting period (2024-2031).
Prostate cancer develops into the male reproductive system. In contrast, Castration-resistant prostate cancer spread to other parts of the body and is resistant to medical or surgical treatment.
Source: Data M Intelligence Analysis (2021)
Castration Resistant Prostate Cancer Treatment Market Dynamics
Emerging novel therapies for the treatment of castration-resistant prostate cancer are expected to drive market growth.
Castrate-resistant prostate cancer (CRPC) occurs when prostate cancer develops to resist standard treatment with androgen deprivation therapy (ADT), which blocks androgens' production and signalling activity (such as testosterone) that fuels cancer's growth. About 10% to 20% of all prostate cancers are CRPCs. Most CRPCs are diagnosed as metastatic (mCRPC), which has already spread beyond the prostate; only about 16% are caught before metastasis (non-metastatic CRPC, or nmCRPC). After CRPC develops, more potent drugs that reduce androgen signalling may help for a while, but cancer eventually resists these as well. Even in CRPC, androgen receptor (AR) signalling remains a crucial driver of tumor growth. Enzalutamide, a second-generation AR antagonist, has become the standard of care for CRPC. Moreover, these drugs have a higher affinity for the AR binding domain and have no agonist action, preventing AR nuclear translocation and decreasing androgen-dependent genes downstream. In phase-3 trials, enzalutamide significantly improved OS and PFS in mCRPC patients compared to placebo, both in chemotherapy-pretreated and chemotherapy-naive patients.
In addition, apalutamide and darolutamide have gained US FDA approval in nmCRPC, based on phase-3 trials showing prolongation of metastasis-free survival (MFS). Therefore, emerging novel therapies have been an advantage for driving the market growth in the forecast period.
Side Effects associated with hormone therapy for the treatment of castration-resistant prostate cancer are likely to hamper the market growth
According to the American Cancer Society, orchiectomy (surgical castration) is a kind of surgery that acts as hormone therapy. Reduced or absent sexual desire, erectile dysfunction (impotence), shrinkage of the testicles and penis, hot flashes, which may improve or disappear with time, breast tenderness and growth of breast tissue (gynecomastia), anemia (low red blood cell counts), decreased mental sharpness, loss of sex drive, and loss of appetite are some of the side effects associated with the therapy. Some of the side effects mentioned above are likely to hamper market growth.
COVID-19 Impact on Castration Resistant Prostate Cancer Treatment Market
The COVID-19 pandemic has impacted practically every phase of cancer care and research, from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research. Moreover, COVID-19 has complicated the treatment for cancer patients. It has also spurred creative solutions to challenges in clinical care. Research into the new disease is benefiting from insights gained over years of cancer research. Further research is needed to recognize the advanced planning and rapid responses to reduce the impact of the pandemic as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.
Castration Resistant Prostate Cancer Treatment Market Segment Analysis
The chemotherapy segment is expected to hold the largest market share in this market segment.
Based on treatment type, the chemotherapy segment held the largest market share in 2020. Prostate cancer in an early stage grows slowly, and treating cancer would cause more problems than the disease itself. So, treatment begins if the results of the tests done during active surveillance show signs of cancer becoming more aggressive or spreading, if cancer causes pain, or if cancer blocks the urinary tract. Chemotherapy is a treatment that uses medications to treat cancer by inhibiting them from growing, dividing, and multiplying. It is beneficial to those who have advanced or castration-resistant prostate cancer and those who have recently been diagnosed with castration-sensitive metastatic prostate cancer. Several standard medications are used to treat prostate cancer, and a chemotherapy regimen, or schedule, usually consists of a specific number of treatments administered over a specified period. Docetaxel (Taxotere) and prednisone are commonly used in chemotherapy drugs. Moreover, recent research showed that adding docetaxel to hormonal therapy in newly diagnosed or castration-sensitive metastatic prostate cancer significantly helps people live longer and stops the disease from growing and spreading.
Source: DataM Intelligence Analysis (2021)
Castration Resistant Prostate Cancer Treatment Market Geographical Share
North America region holds the largest market share in the global castration-resistant prostate cancer treatment market.
North America dominated the market and accounted for the largest revenue share in 2020. The segment growth is attributed to the large prostate cancer population in this region and developed medical facilities. For instance, according to the American Cancer Society, prostate cancer is the second leading cause of cancer death in American men. The estimates for prostate cancer in the United States for 2021 are about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.
Moreover, about 1 man in 8 will be diagnosed with prostate cancer during his lifetime and is more likely to develop in older men and non-Hispanic Black men. About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. In addition, increasing demand for a diagnostic test, increasing awareness among people and initiatives taken by the federal government are also contributing to the growth of the market in this region.
Source: DataM Intelligence Analysis (2021)
Global Castration Resistant Prostate Cancer Treatment Market Competitive Landscape
Major key players in the castration-resistant prostate cancer treatment market are Active Biotech AB, Diagnocure, Glaxosmithkline PLC, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories and Bayer Healthcare Pharmaceuticals.
Bayer Healthcare Pharmaceuticals:
Overview: Bayer AG is a German multinational pharmaceutical and Life Sciences Company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company concentrates its R&D activities on innovative treatment alternatives to improve patients' quality of life and prolong lives. In 2020, the Bayer Group comprised 385 consolidated companies in 83 countries. Moreover, in Germany, the company had 23,398 (2019: 24,953) employees, 23.5% of the total Bayer Group workforce.
Product Portfolio:
Bayer Healthcare Pharmaceuticals has developed an alpha-particle emitting radioactive therapeutic agent to treat castration-resistant prostate cancer treatment (CRPC) and symptomatic bone metastases.
Key Development:
On 3rd April 2020, the European Commission approved Bayer Healthcare Pharmaceuticals' new androgen receptor inhibitor (ARi) with a distinct chemical structure that delays disease progression while reducing treatment's burdensome side effects, allowing men with non-metastatic castration-resistant prostate cancer (nmCRPC) to maintain their lifestyle without disruptions. The therapy has previously been approved in the United States, Australia, Brazil, Canada, and Japan, and additional health authorities are currently evaluating it across the world.
Why Purchase the Report?
- Visualize the composition of the global castration resistant prostate cancer treatment market segmentation by treatment, end-users and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the global castration resistant prostate cancer treatment market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of global castration resistant prostate cancer treatment market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global castration resistant prostate cancer treatment market report would provide an access to an approx.45+ market data table, 40+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
